Want to join the conversation?
$REGN and $SNY closed enrollment in global Phase 3 Odyssey Outcomes Trial, which is prospectively evaluating potential cardiovascular (CV) benefits of Praluent (alirocumab) Injection after acute coronary syndrome (ACS). The 18,000-patient trial is seen to be closed in 2017. Praluent is now approved in the U.S. and EU to reduce bad cholesterol.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.